The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1

Lisa Derosa; Bertrand Routy; Guido Kroemer; Laurence Zitvogel

doi:10.1080/2162402X.2018.1434468

The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1

Oncoimmunology. 2018 Apr 18;7(6):e1434468. doi: 10.1080/2162402X.2018.1434468. eCollection 2018.

Authors

Lisa Derosa^{1

2

3

4}, Bertrand Routy^{1

2

3

4

5

6}, Guido Kroemer^{7

8

9

10

11

12

10

13}, Laurence Zitvogel^{1

2

3

4

5

6

7

8

9

10

11

12

10

13

14}

Affiliations

¹ Gustave Roussy Cancer Campus (GRCC), Villejuif, France.
² Institut National de la Santé Et de la Recherche Medicale (INSERM), Villejuif, France.
³ Equipe Labellisée-Ligue Nationale contre le Cancer, Villejuif, France.
⁴ Univ. Paris-Sud, Université Paris-Saclay, Gustave Roussy, Villejuif, France.
⁵ Hematology-Oncology Division, Department of Medicine, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Qc, Canada.
⁶ Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Montréal, Qc, Canada.
⁷ Metabolomics and Cell Biology Platforms, GRCC, Villejuif, France.
⁸ Paris Descartes University, Sorbonne Paris Cité, Paris, France.
⁹ Equipe 11 Labellisée-Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, INSERM, Paris, France.
¹⁰ Pôle de Biologie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.
¹¹ Institut National de la Santé et de la Recherche Médicale, Paris, France.
¹² Pierre et Marie Curie University, Paris, France.
¹³ Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden.
¹⁴ Center of Clinical Investigations in Biotherapies of Cancer (CICBT), Villejuif, France.

Abstract

Cancer immunotherapists have been searching for biomarkers predicting patient responses to PD-1/PD-L1 blockade in neoplastic cells as well as in the immune system. Now, accumulating evidence indicates that the composition of the intestinal microflora has a major impact on patient prognosis. Here, we enumerate the bacterial species that are associated with favorable outcome of immunotherapy.

Keywords: Biomarkers; Inflammation and cancer; Microbiota; NSCLC; New target; PD-1/PD-L1; RCC; immune checkpoint blockers.

Publication types

Research Support, Non-U.S. Gov't